Non‐invasive Fibrosis Markers for Chronic Hepatitis B in Sub‐saharan Africa

Rui Huang,Bei Jia,Guiyang Wang,Chao Wu

DOI: https://doi.org/10.1111/liv.13410

IF: 8.754

2017-01-01

Liver International

Abstract:To the editor, We read with great interest the article by Desalegn H et al.,1 in which they determined the potential diagnostic accuracy of aspartate aminotransferase to platelet ratio index (APRI), fibrosis4 score (FIB4) and gammaglutamyl transpeptidase to platelet ratio (GPR) in one of the largest chronic hepatitis B (CHB) cohorts in subSaharan Africa.1 They concluded that APRI, FIB4 and GPR were valuable for the diagnosis of liver fibrosis and cirrhosis in CHB patients in subSaharan Africa.1 However, the sensitivity for detecting fibrosis and cirrhosis was relatively low.1 These findings are interesting, because few studies have identified these noninvasive fibrosis biomarkers in subSaharan Africa. However, the results should be interpreted with cautions. Firstly, in this study transient elastography (TE) was used as a reference to define significant fibrosis and cirrhosis.1 Although TE has been widely evaluated in CHB patients, there is still lack of uniformly established standard to identify specific stages of liver fibrosis.2,3 In addition, several factors may affect the accuracy of TE. Indeed, the authors have excluded patients with ascites, overweight or obesity in this study, as fluid and adipose tissue may attenuate the elastic wave.1 However, other factors, such as sex (men tend to have higher liver stiffness than women), metabolic syndrome and experience of different operators may also influence the test results.3 Thus, a potential bias of liver fibrosis stages might exist in the study. Although, as the authors mentioned, sampling errors may lead to poor reproducibility for liver biopsies, liver histology remains the gold standard to determine liver fibrosis in clinical research.2,3 Secondly, the authors used 0.5 and 1.5 to distinguish F01 and F24,1.0 and 2.0 to differentiate F03 and F4 for APRI, 1.45 and 3.25 to distinguish F02 and F34 for FIB4.1 However, the above thresholds were developed from patients with chronic hepatitis C virus infection.4,5 These cutoff values have not been well validated among CHB patients. Thirdly, all the noninvasive fibrosis biomarkers in the study included platelets as a critical component.1 However, platelet count is pronouncedly influenced by various factors including chronic inflammatory diseases, haematological disorders and drug usage, which creates difficulty for further calculation of APRI, FIB4 and GPR, the biomarkers proposed in this study. In summary, further validation is essential for potential clinical application of these noninvasive biomarkers for liver fibrosis from CHB patients in subSaharan Africa.